December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

41.12 +0.26 (+0.64%)
Streaming Delayed Price Updated: 3:15 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Pricing of Upsized $650 Million Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Proposed Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Seasoned public company CFO with 25 years of leadership experience in biotech 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.